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Liposomes, sphere-shaped vesicles consisting of one or more phospholipid bilayers, were first described in the mid-
60s. Today, they are a very useful reproduction, reagent, and tool in various scientific disciplines, including
mathematics and theoretical physics, biophysics, chemistry, colloid science, biochemistry, and biology. Since then,
liposomes have made their way to the market. Among several talented new drug delivery systems, liposomes
characterize an advanced technology to deliver active molecules to the site of action, and at present, several
formulations are in clinical use. Research on liposome technology has progressed from conventional vesicles to
‘second-generation liposomes’, in which long-circulating liposomes are obtained by modulating the lipid
composition, size, and charge of the vesicle. Liposomes with modified surfaces have also been developed using
several molecules, such as glycolipids or sialic acid. This paper summarizes exclusively scalable techniques and
focuses on strengths, respectively, limitations in respect to industrial applicability and regulatory requirements
concerning liposomal drug formulations based on FDA and EMEA documents.
Keywords: Liposomes, Glycolipids, Drug formulations, Drug delivery systemsReview
Introduction
Liposomes are small artificial vesicles of spherical shape
that can be created from cholesterol and natural non-
toxic phospholipids. Due to their size and hydrophobic
and hydrophilic character(besides biocompatibility),
liposomes are promising systems for drug delivery. Lipo-
some properties differ considerably with lipid compos-
ition, surface charge, size, and the method of
preparation (Table 1). Furthermore, the choice of bilayer
components determines the ‘rigidity’ or ‘fluidity’ and the
charge of the bilayer. For instance, unsaturated phos-
phatidylcholine species from natural sources (egg or
soybean phosphatidylcholine) give much more perme-
able and less stable bilayers, whereas the satu-
rated phospholipids with long acyl chains (for example,* Correspondence: akbarzadehab@tbzmed.ac.ir; swjoo@yu.ac.kr; zarghami@
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reproduction in any medium, provided the origdipalmitoylphos phatidylcholine) form a rigid, rather im-
permeable bilayer structure [1-3].
It has been displayed that phospholipids impulsively
form closed structures when they are hydrated in aque-
ous solutions. Such vesicles which have one or more
phospholipid bilayer membranes can transport aqueous
or lipid drugs, depending on the nature of those drugs.
Because lipids are amphipathic (both hydrophobic and
hydrophilic) in aqueous media, their thermodynamic
phase properties and self assembling characteristics in-
fluence entropically focused confiscation of their hydro-
phobic sections into spherical bilayers. Those layers are
referred to as lamellae [4]. Generally, liposomes are def-
inite as spherical vesicles with particle sizes ranging from
30 nm to several micrometers. They consist of one or
more lipid bilayers surrounding aqueous units, where
the polar head groups are oriented in the pathway of the
interior and exterior aqueous phases. On the other hand,
self-aggregation of polar lipids is not limited to conven-
tional bilayer structures which rely on molecular shape,
temperature, and environmental and preparation con-
ditions but may self-assemble into various types of col-
loidal particles [5].is is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Table 1 Advantages and disadvantages of liposome [19]
Advantages of liposome Disadvantages of liposome
Liposomes increased efficacy and therapeutic index of drug (actinomycin-D) Low solubility
Liposome increased stability via encapsulation Short half-life
Liposomes are non-toxic, flexible, biocompatible, completely biodegradable, and non-
immunogenic for systemic and non-systemic administrations
Sometimes phospholipid undergoes oxidation
and hydrolysis-like reaction
Liposomes reduce the toxicity of the encapsulated agent (amphotericin B, Taxol) Leakage and fusion of encapsulated drug/
molecules
Liposomes help reduce the exposure of sensitive tissues to toxic drugs Production cost is high
Site avoidance effect Fewer stables
Flexibility to couple with site-specific ligands to achieve active targeting
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ous molecules in cosmetic and pharmaceutical indus-
tries. Additionally, food and farming industries have
extensively studied the use of liposome encapsulation
to grow delivery systems that can entrap unstable
compounds (for example, antimicrobials, antioxidants,
flavors and bioactive elements) and shield their func-
tionality. Liposomes can trap both hydrophobic and
hydrophilic compounds, avoid decomposition of the en-
trapped combinations, and release the entrapped at
designated targets [6-8].
Because of their biocompatibility, biodegradability, low
toxicity, and aptitude to trap both hydrophilic and lipo-
philic drugs [9] and simplify site-specific drug delivery
to tumor tissues [10], liposomes have increased rate both
as an investigational system and commercially as a drug-
delivery system. Many studies have been conducted on
liposomes with the goal of decreasing drug toxicity and/
or targeting specific cells [11-13].
Liposomal encapsulation technology (LET) is the
newest delivery technique used by medical investigators
to transmit drugs that act as curative promoters to the
assured body organs. This form of delivery system pro-
posal targeted the delivery of vital combinations to the
body. LET is a method of generating sub-microscopic
foams called liposomes, which encapsulate numerous
materials. These ‘liposomes’ form a barrier around their
contents, which is resistant to enzymes in the mouth
and stomach, alkaline solutions, digestive juices, bile
salts, and intestinal flora that are generated in the
human body, as well as free radicals. The contents of the
liposomes are, therefore, protected from oxidation and
degradation. This protective phospholipid shield or bar-
rier remains undamaged until the contents of the lipo-
some are delivered to the exact target gland, organ, or
system where the contents will be utilized [14].
Clinical medication keeps an enormously broad range
of drug molecules at this time in use, and new drugs are
added to the list every year. One of the main aims of any
cure employing drug is to increase the therapeutic index
of the drug while minimizing its side effects. The clinicalusefulness of most conservative chemotherapeutics is
restricted either by the incapability to deliver therapeutic
drug concentrations to the target soft tissue or by Spar-
tan and harmful toxic side effects on normal organs and
tissues. Different approaches have been made to over-
come these difficulties by providing the ‘selective’ deliv-
ery to the target area; the ideal solution would be to
target the drug alone to those cells, tissues, organs that
are affected by the disease. Selected carriers, for instance
colloidal particulates and molecular conjugates, can be
appropriate for this determination. Colloidal particu-
lates result from the physical incorporation of the drug
into a particulate colloidal system, for instance reverse
micelles, noisome, micro- and nano-spheres, erythro-
cytes, and polymers and liposomes. Among these car-
riers, liposomes have been most studied. Their
attractiveness lies in their composition, which makes
them biodegradable and biocompatible. Liposome
involves an aqueous core entrapped by one or more
bilayers composed of natural or synthetic lipids. They
are composed of natural phospholipids that are biologic-
ally inert and feebly immunogenic, and they have low in-
herent toxicity. Furthermore, drugs with different
lipophilicities can be encapsulated into liposomes:
strongly lipophilic drugs are entrapped almost totally in
the lipid bilayer, intensely hydrophilic drugs are located
entirely in the aqueous compartment, and drugs with
intermediary logP effortlessly partition between the lipid
and aqueous phases, both in the bilayer and in the aque-
ous core [15].
The present review will briefly explain the charac-
teristics of liposomes and explore the related problems
and solutions proposed, with a focus on liposome prep-
aration, characterizations, affecting factors, advantages,
and disadvantages. In particular, we return to the litera-
ture relating to high-stability, long-circulating liposomes
(stealth liposomes), and their field of application.
Classification of liposomes
The liposome size can vary from very small (0.025 μm)
to large (2.5 μm) vesicles. Moreover, liposomes may have
Akbarzadeh et al. Nanoscale Research Letters 2013, 8:102 Page 3 of 9
http://www.nanoscalereslett.com/content/8/1/102one or bilayer membranes. The vesicle size is an acute
parameter in determining the circulation half-life of
liposomes, and both size and number of bilayers affect
the amount of drug encapsulation in the liposomes. On
the basis of their size and number of bilayers, liposomes
can also be classified into one of two categories: (1)
multilamellar vesicles (MLV) and (2) unilamellar vesi-
cles. Unilamellar vesicles can also be classified into two
categories: (1) large unilamellar vesicles (LUV) and (2)
small unilamellar vesicles (SUV) [16]. In unilamellar
liposomes, the vesicle has a single phospholipid bilayer
sphere enclosing the aqueous solution. In multilamellar
liposomes, vesicles have an onion structure. Classically,
several unilamellar vesicles will form on the inside of the
other with smaller size, making a multilamellar structure
of concentric phospholipid spheres separated by layers
of water [17].
Methods of liposome preparation
General methods of preparation
All the methods of preparing the liposomes involve four
basic stages:
1. Drying down lipids from organic solvent.
2. Dispersing the lipid in aqueous media.
3. Purifying the resultant liposome.
4. Analyzing the final product.
Method of liposome preparation and drug loading
The following methods are used for the preparation of
liposome:
1. Passive loading techniques
2. Active loading technique.
Passive loading techniques include three different
methods:
1. Mechanical dispersion method.
2. Solvent dispersion method.
3. Detergent removal method (removal of non-
encapsulated material) [18,19].
Mechanical dispersion method
The following are types of mechanical dispersion
methods:
1.1. Sonication.
1.2. French pressure cell: extrusion.
1.3. Freeze-thawed liposomes.
1.4. Lipid film hydration by hand shaking, non-hand.
shaking or freeze drying.
1.5. Micro-emulsification.
1.6. Membrane extrusion.1.7. Dried reconstituted vesicles [18,19].
Sonication Sonication is perhaps the most extensively
used method for the preparation of SUV. Here, MLVs
are sonicated either with a bath type sonicator or a
probe sonicator under a passive atmosphere. The main
disadvantages of this method are very low internal vol-
ume/encapsulation efficacy, possible degradation of
phospholipids and compounds to be encapsulated, elim-
ination of large molecules, metal pollution from probe
tip, and presence of MLV along with SUV [18].
There are two sonication techniques:
a) Probe sonication. The tip of a sonicator is directly
engrossed into the liposome dispersion. The energy
input into lipid dispersion is very high in this
method. The coupling of energy at the tip results in
local hotness; therefore, the vessel must be engrossed
into a water/ice bath. Throughout the sonication up
to 1 h, more than 5% of the lipids can be de-
esterified. Also, with the probe sonicator, titanium
will slough off and pollute the solution.
b) Bath sonication. The liposome dispersion in a
cylinder is placed into a bath sonicator. Controlling
the temperature of the lipid dispersion is usually
easier in this method, in contrast to sonication by
dispersal directly using the tip. The material being
sonicated can be protected in a sterile vessel,
dissimilar the probe units, or under an inert
atmosphere [20].
French pressure cell: extrusion French pressure cell
involves the extrusion of MLV through a small orifice
[18]. An important feature of the French press vesicle
method is that the proteins do not seem to be signifi-
cantly pretentious during the procedure as they are in
sonication [21]. An interesting comment is that French
press vesicle appears to recall entrapped solutes signifi-
cantly longer than SUVs do, produced by sonication or
detergent removal [22-24].
The method involves gentle handling of unstable
materials. The method has several advantages over son-
ication method [25]. The resulting liposomes are rather
larger than sonicated SUVs. The drawbacks of the
method are that the high temperature is difficult to at-
tain, and the working volumes are comparatively small
(about 50 mL as the maximum) [18,19].
Freeze-thawed liposomes SUVs are rapidly frozen and
thawed slowly. The short-lived sonication disper-
ses aggregated materials to LUV. The creation of
unilamellar vesicles is as a result of the fusion of SUV
throughout the processes of freezing and thawing
[26-28]. This type of synthesis is strongly inhibited by
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creasing the ionic strength of the medium. The encapsu-
lation efficacies from 20% to 30% were obtained [26].
Solvent dispersion method
Ether injection (solvent vaporization) A solution of
lipids dissolved in diethyl ether or ether-methanol mix-
ture is gradually injected to an aqueous solution of the
material to be encapsulated at 55°C to 65°C or under
reduced pressure. The consequent removal of ether
under vacuum leads to the creation of liposomes. The
main disadvantages of the technique are that the popula-
tion is heterogeneous (70 to 200 nm) and the exposure
of compounds to be encapsulated to organic solvents at
high temperature [29,30].
Ethanol injection A lipid solution of ethanol is rapidly
injected to a huge excess of buffer. The MLVs are at
once formed. The disadvantages of the method are that
the population is heterogeneous (30 to 110 nm),
liposomes are very dilute, the removal all ethanol is
difficult because it forms into azeotrope with water, and
the probability of the various biologically active
macromolecules to inactivate in the presence of even
low amounts of ethanol is high [31].
Reverse phase evaporation method This method
provided a progress in liposome technology, since it
allowed for the first time the preparation of liposomes
with a high aqueous space-to-lipid ratio and a capability
to entrap a large percentage of the aqueous material
presented. Reverse-phase evaporation is based on the
creation of inverted micelles. These inverted micelles are
shaped upon sonication of a mixture of a buffered aque-
ous phase, which contains the water-soluble molecules
to be encapsulated into the liposomes and an organic
phase in which the amphiphilic molecules are
solubilized. The slow elimination of the organic solvent
leads to the conversion of these inverted micelles into
viscous state and gel form. At a critical point in this
process, the gel state collapses, and some of the inverted
micelles were disturbed. The excess of phospholipids in
the environment donates to the formation of a complete
bilayer around the residual micelles, which results in the
creation of liposomes. Liposomes made by reverse phase
evaporation method can be made from numerous lipid
formulations and have aqueous volume-to-lipid ratios
that are four times higher than hand-shaken liposomes
or multilamellar liposomes [19,20].
Briefly, first, the water-in-oil emulsion is shaped by
brief sonication of a two-phase system, containing
phospholipids in organic solvent such as isopropyl ether
or diethyl ether or a mixture of isopropyl ether andchloroform with aqueous buffer. The organic solvents
are detached under reduced pressure, resulting in the
creation of a viscous gel. The liposomes are shaped
when residual solvent is detached during continued ro-
tary evaporation under reduced pressure. With this
method, high encapsulation efficiency up to 65% can be
obtained in a medium of low ionic strength for example
0.01 M NaCl. The method has been used to encapsulate
small, large, and macromolecules. The main drawback of
the technique is the contact of the materials to be
encapsulated to organic solvents and to brief periods of
sonication. These conditions may possibly result in the
breakage of DNA strands or the denaturation of some
proteins [32]. Modified reverse phase evaporation
method was presented by Handa et al., and the main
benefit of the method is that the liposomes had high en-
capsulation efficiency (about 80%) [33].
Detergent removal method (removal of non-encapsulated
material)
Dialysis The detergents at their critical micelle
concentrations (CMC) have been used to solubilize
lipids. As the detergent is detached, the micelles become
increasingly better-off in phospholipid and lastly com-
bine to form LUVs. The detergents were removed by
dialysis [34-36]. A commercial device called LipoPrep
(Diachema AG, Switzerland), which is a version of
dialysis system, is obtainable for the elimination of
detergents. The dialysis can be performed in dialysis
bags engrossed in large detergent free buffers (equilib-
rium dialysis) [17].
Detergent (cholate, alkyl glycoside, Triton X-100) re-
moval of mixed micelles (absorption) Detergent
absorption is attained by shaking mixed micelle solution
with beaded organic polystyrene adsorbers such
as XAD-2 beads (SERVA Electrophoresis GmbH,
Heidelberg, Germany) and Bio-beads SM2 (Bio-Rad
Laboratories, Inc., Hercules, USA). The great benefit of
using detergent adsorbers is that they can eliminate
detergents with a very low CMC, which are not entirely
depleted.
Gel-permeation chromatography In this method, the
detergent is depleted by size special chromatography.
Sephadex G-50, Sephadex G-l 00 (Sigma-Aldrich, MO,
USA), Sepharose 2B-6B, and Sephacryl S200-S1000
(General Electric Company, Tehran, Iran) can be used
for gel filtration. The liposomes do not penetrate into
the pores of the beads packed in a column. They perco-
late through the inter-bead spaces. At slow flow rates,
the separation of liposomes from detergent monomers is
very good. The swollen polysaccharide beads adsorb
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treatment is necessary. The pre-treatment is done by
pre-saturation of the gel filtration column by lipids using
empty liposome suspensions.
Dilution
Upon dilution of aqueous mixed micellar solution of de-
tergent and phospholipids with buffer, the micellar size
and the polydispersity increase fundamentally, and as
the system is diluted beyond the mixed micellar phase
boundary, a spontaneous transition from poly-dispersed
micelles to vesicles occurs.
Stealth liposomes and conventional liposomes
Although liposomes are like biomembranes, they are still
foreign objects of the body. Therefore, liposomes are
known by the mononuclear phagocytic system (MPS)
after contact with plasma proteins. Accordingly, lipo-
somes are cleared from the blood stream.
These stability difficulties are solved through the use
of synthetic phospholipids, particle coated with amphi-
pathic polyethylene glycol, coating liposomes with chitin
derivatives, freeze drying, polymerization, micro-encap-
sulation of gangliosides [17].
Coating liposomes with PEG reduces the percentage of
uptake by macrophages and leads to a prolonged pres-
ence of liposomes in the circulation and, therefore, make
available abundant time for these liposomes to leak from
the circulation through leaky endothelium.
A stealth liposome is a sphere-shaped vesicle with a
membrane composed of phospholipid bilayer used to de-
liver drugs or genetic material into a cell. A liposome
can be composed of naturally derived phospholipids with
mixed lipid chains coated or steadied by polymers of
PEG and colloidal in nature. Stealth liposomes are
attained and grown in new drug delivery and in con-
trolled release. This stealth principle has been used to
develop the successful doxorubicin-loaded liposome
product that is presently marketed as Doxil (Janssen
Biotech, Inc., Horsham, USA) or Caelyx (Schering-
Plough Corporation, Kenilworth, USA) for the treatment
of solid tumors. Recently impressive therapeutic impro-
vements were described with the useof corticosteroid-
loaded liposome in experimental arthritic models. The
concerning on the application of stealth liposomes has
been on their potential to escape from the blood circula-
tion. However, long circulating liposome may also act as
a reservoir for prolonged release of a therapeutic agent.
Pharmacological action of vasopressin is formulated in
long circulating liposome [37,38].
Drug loading in liposomes
Drug loading can be attained either passively (i.e., the
drug is encapsulated during liposome formation) oractively (i.e., after liposome formation). Hydrophobic
drugs, for example amphotericin B taxol or annamycin,
can be directly combined into liposomes during vesicle
formation, and the amount of uptake and retention is
governed by drug-lipid interactions. Trapping effective-
ness of 100% is often achievable, but this is dependent
on the solubility of the drug in the liposome membrane.
Passive encapsulation of water-soluble drugs depends on
the ability of liposomes to trap aqueous buffer
containing a dissolved drug during vesicle formation.
Trapping effectiveness (generally <30%) is limited by the
trapped volume delimited in the liposomes and drug
solubility. On the other hand, water-soluble drugs that
have protonizable amine functions can be actively en-
trapped by employing pH gradients [39], which can re-
sult in trapping effectiveness approaching 100% [40].
Freeze-protectant for liposomes (lyophilization)
Natural excerpts are usually degraded because of oxida-
tion and other chemical reactions before they are
delivered to the target site. Freeze-drying has been a
standard practice employed to the production of many
pharmaceutical products. The overwhelming majority of
these products are lyophilized from simple aqueous
solutions. Classically, water is the only solvent that must be
detached from the solution using the freeze-drying process,
but there are still many examples where pharmaceutical
products are manufactured via a process that requires
freeze-drying from organic co-solvent systems [14].
Freeze-drying (lyophilization) involves the removal of
water from products in the frozen state at tremendously
low pressures. The process is normally used to dry
products that are thermo-labile and would be demo-
lished by heat-drying. The technique has too much
potential as a method to solve long-term stability diffi-
culties with admiration to liposomal stability. Studies
showed that leakage of entrapped materials may take
place during the process of freeze-drying and on recon-
stitution. Newly, it was shown that liposomes when
freeze-dried in the presence of adequate amounts of tre-
halose (a carbohydrate commonly found at high
concentrations in organism) retained as much as 100%
of their original substances. It shows that trehalose is an
excellent cryoprotectant (freeze-protectant) for lipo-
somes. Freeze-driers range in size from small laboratory
models to large industrial units available from pharma-
ceutical equipment suppliers [41].
Mechanism of transportation through liposome
The limitations and benefits of liposome drug carriers
lie critically on the interaction of liposomes with cells
and their destiny in vivo after administration. In vivo
and in vitro studies of the contacts with cells have
shown that the main interaction of liposomes with cells
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cell-surface components, electrostatic forces, or by non-
specific weak hydrophobic) or following endocytosis (by
phagocytic cells of the reticuloendothelial system, for ex-
ample macrophages and neutrophils).
Fusion with the plasma cell membrane by insertion of
the lipid bilayer of the liposome into the plasma mem-
brane, with simultaneous release of liposomal content into
the cytoplasm, is much rare. The fourth possible inter-
action is the exchange of bilayer components, for instance
cholesterol, lipids, and membrane-bound molecules with
components of cell membranes. It is often difficult to de-
termine what mechanism is functioning, and more than
one may function at the same time [42-44].
Fusogenic liposomes and antibody-mediated liposomes in
cancer therapy
It has been infrequently well-known that a powerful
anticancer drug, especially one that targets the cyto-
plasm or cell nucleus, does not work due to the low per-
meability across a plasma membrane, degradation by
lysosomal enzymes through an endocytosis-dependent
pathway, and other reasons. Thus, much attention on
the use of drug delivery systems is focused on overcom-
ing these problems, ultimately leading to the induction
of maximal ability of anti-cancer drug. In this respect, a
new model for cancer therapy using a novel drug deliv-
ery system, fusogenic liposome [45], was developed.
Fusogenic liposomes are poised of the ultraviolet-
inactivated Sendai virus and conventional liposomes.
Fusogenic liposomes effectively and directly deliver their
encapsulated contents into the cytoplasm using a fusion
mechanism of the Sendai virus, whereas conventional
liposomes are taken up by endocytosis by phagocytic
cells of the reticuloendothelial system, for example
macrophages and neutrophils. Thus, fusogenic liposome
is a good candidate as a vehicle to deliver drugs into the
cytoplasm in an endocytosis-independent manner [45].
Liposomal drug delivery systems provide steady
formulation, provide better pharmacokinetics, and make
a degree of ‘passive’ or ‘physiological’ targeting to tumor
tissue available. However, these transporters do not
directly target tumor cells. The design modifications that
protect liposomes from unwanted interactions with
plasma proteins and cell membranes which differed
them with reactive carriers, for example cationic
liposomes, also prevent interactions with tumor cells. As
an alternative, after extravasation into tumor tissue,
liposomes remain within tumor stroma as a drug-loaded
depot. Liposomes ultimately become subject to enzym-
atic degradation and/or phagocytic attack, leading to re-
lease of drug for subsequent diffusion to tumor cells.
The next generation of drug carriers under development
features directs molecular targeting of cancer cells viaantibody-mediated or other ligand-mediated interactions
[17,45].Applications of liposomes in medicine and pharmacology
Applications of liposomes in medicine and pharmacol-
ogy can be divided into diagnostic and therapeutic
applications of liposomes containing various markers or
drugs, and their use as a tool, a model, or reagent in the
basic studies of cell interactions, recognition processes,
and mode of action of certain substances [43].
Unfortunately, many drugs have a very narrow thera-
peutic window, meaning that the therapeutic concentra-
tion is not much lower than the toxic one. In several
cases, the toxicity can be reduced or the efficacy can be
enhanced by the use of a suitable drug carrier which
alters the temporal and spatial delivery of the drug, i.e.,
its biodistribution and pharmacokinetics. It is clear from
many pre-clinical and clinical studies that drugs, for
instance antitumor drugs, parceled in liposome demon-
stration reduced toxicities, while retentive enhanced
efficacy.
Advances in liposome design are leading to new
applications for the delivery of new biotechnology
products, for example antisense oligonucleotides, cloned
genes, and recombinant proteins. A vast literature define
the viability of formulating wide range of conservative
drugs in liposomes, frequently resultant in improved
therapeutic activity and/or reduced toxicity compared
with the free drug. As a whole, changed pharmacokinet-
ics for liposomal drugs can lead to improved drug bio-
availability to particular target cells that live in the
circulation, or more prominently, to extravascular dis-
ease sites, for example, tumors. Recent improvements
include liposomal formulations of all-trans-retinoic acid
[46,47] and daunorubicin [48-51], which has received
Food and Drug Administration consent as a first-line
treatment of AIDS-related advanced Kaposi's sarcoma.
Distinguished examples are vincristine, doxorubicin, and
amphotericin B [38].
The benefits of drug load in liposomes, which can be
applied as (colloidal) solution, aerosol, or in (semi) solid
forms, such as creams and gels, can be summarized into
seven categories [44] (Table 2):Liposomes in parasitic diseases and infections
From the time when conventional liposomes are
digested by phagocytic cells in the body after intraven-
ous management, they are ideal vehicles for the targeting
drug molecules into these macrophages. The best known
instances of this ‘Trojan horse-like’ mechanism are sev-
eral parasitic diseases which normally exist in the cell of
MPS. They comprise leishmaniasis and several fungal
infections.
Table 2 Benefits of drug load in liposomes
Benefits of drug load in liposome Examples
1. Improved solubility of lipophilic and amphiphilic drugs Amphotericin B, porphyrins, minoxidil, some peptides, and anthracyclines,
respectively; hydrophilic drugs, such as anticancer agent doxorubicin or acyclovir
2. Passive targeting to the cells of the immune system,
especially cells of the mononuclear phagocytic system
Antimonials, amphotericin B, porphyrins, vaccines, immunomodulators
3. Sustained release system of systemically or locally
administered liposomes
Doxorubicin, cytosine arabinoside, cortisones, biological proteins or peptides such
as vasopressin
4. Site-avoidance mechanism Doxorubicin andamphotericin B
5. Site-specific targeting Anti-inflammatory drugs, anti-cancer, anti-infection
6. Improved transfer of hydrophilic, charged molecules Antibiotics, chelators, plasmids, and genes
7. Improved penetration into tissues Corticosteroids, anesthetics, and insulin
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which affects over 100 million people in tropical regions
and is often deadly. The effectual dose of drugs, mostly
different antimonials, is not much lower than the toxic
one. Liposomes accumulate in the very same cell popu-
lation which is infected, and so an ideal drug delivery ve-
hicle was proposed [52]. Certainly, the therapeutic index
was increased in rodents as much as several hundred
times upon administration of the drug in various
liposomes. Unexpectedly, and unfortunately, there was
not much interest to scale up the formulations and clin-
ically approve them after several very encouraging stud-
ies dating back to 1978. Only now, there are several
continuing studies with various anti-parasitic liposome
formulations in humans. These formulations use mostly
ionosphere amphotericin B and are transplanted from
very successful and prolific area of liposome formu-
lations in antifungal therapy.
The best results reported so far in human therapy are
probably liposomes as carriers foramphotericin B in
antifungal therapies. This is the drug of choice in
dispersed fungal infections which often in parallel work
together with chemotherapy, immune system, or AIDS,
and is frequently fatal. Unfortunately, the drug itself is
very toxic and its dosage is limited due to its ionosphere
and neurotoxicity. These toxicities are normally related
with the size of the drug molecule or its complex. Obvi-
ously, liposome encapsulation inhibits the accumulation
of drug in these organs and radically reduces toxicity [53].
Furthermore, often, the fungus exists in the cells of the
mononuclear phagocytic system; therefore, the encapsula-
tion results in reduced toxicity and passive targeting.
These benefits, however, can be associated with any
colloidal drug carrier. Certainly, similar improvements
in therapy were observed with stable mixed micellar
formulations and micro-emulsions [54]. Additionally, it
seems that many of the early liposomal preparations were
in actual fact liquid crystalline colloidal particles rather
than self-closed MLV. Since the lives of the first terminally
ill patients (who did not rely to all the conventionaltherapies) were saved [53], many patients were very effect-
ively treated with diverse of amphotericin B formulations.
Comparable methods can be achieved in antiviral and
antibacterial therapies [55]. Most of the antibiotics, how-
ever, are orally available; liposome encapsulation can be
considered only in the case of very potent and toxic ones
which are administered parenterally. The preparation of
antibiotic-loaded liposomes at sensibly high drug-to-lipid
ratios may not be easy because of the interactions of
these molecules with bilayers and high densities of their
aqueous solutions which often force liposomes to float
as a creamy layer on the top of the tube. Several other
ways, for instance, topical or pulmonary (by inhalation)
administration are being considered also. Liposome-
encapsulated antivirals (for example ribavirin, azidothy-
midine, or acyclovir) have also shown to reduce toxicity;
currently, more detailed experiments are being per-
formed in relation to their efficacy.
Liposomes in anticancer therapy
Numerous different liposome formulations of numerous
anticancer agents were shown to be less toxic than the
free drug [56-59]. Anthracyclines are drugs which stop
the growth of dividing cells by intercalating into the
DNA and, thus, kill mainly rapidly dividing cells. These
cells are not only in tumors but are also in hair, gastro-
intestinal mucosa, and blood cells; therefore, this class of
drug is very toxic. The most used and studied is
Adriamycin (commercial name for doxorubicin HCl;
Ben Venue Laboratories, Bedford, Ohio). In addition to
the above-mentioned acute toxicities, its dosage is
limited by its increasing cardio toxicity. Numerous di-
verse formulations were tried. In most cases, the toxicity
was reduced to about 50%. These include both acute
and chronic toxicities because liposome encapsulation
reduces the delivery of the drug molecules towards those
tissues. For the same reason, the efficiency was in many
cases compromised due to the reduced bioavailability of
the drug, especially if the tumor was not phagocytic or
located in the organs of mononuclear phagocytic system.
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liposome encapsulation showed enhanced efficacy due to
the continued release effect, i.e., longer presence of
therapeutic concentrations in the circulation [60-62],
while in several other cases, the sequestration of the
drug into tissues of mononuclear phagocytic system ac-
tually reduced its efficacy.
Applications in man showed, in general, reduced tox-
icity and better tolerability of administration with not too
encouraging efficacy. Several different formulations are in
different phases of clinical studies and show mixed results.
Conclusions
Liposomes have been used in a broad range of pharmaceut-
ical applications. Liposomes are showing particular promise
as intracellular delivery systems for anti-sense molecules,
ribosomes, proteins/peptides, and DNA. Liposomes with
enhanced drug delivery to disease locations, by ability of
long circulation residence times, are now achieving clinical
acceptance. Also, liposomes promote targeting of particular
diseased cells within the disease site. Finally, liposomal
drugs exhibit reduced toxicities and retain enhanced effi-
cacy compared with free complements. Only time will tell
which of the above applications and speculations will prove
to be successful. However, based on the pharmaceutical
applications and available products, we can say that
liposomes have definitely established their position in mod-
ern delivery systems.
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